4th Gamma Delta T Therapies Summit 2023

The gamma delta T wave is cresting as industry leaders such as Adicet Bio, Leucid, Century, Imcheck, IN8bio, Sanofi and Takeda race to demonstrate the clinical benefit and efficacy of gamma delta T therapies, spanning cell-based to antibody and small molecule approaches. Spurred by early evidence of clinical efficacy, the industry returns in 2023 armed with more subset-specific and clinical mechanistic understanding, snowballing investment, and growing expert end-to-end teams. This is the prime time to gather with the gamma delta T therapies industry to contrast subsets, characterize mechanisms of action, and optimize product design to develop globally accessible, solid tumor therapies.

Ensure you don't miss this comprehensive, forward-facing summit, bringing together 150+ gamma delta T pioneers with 40+ industry-leading speakers including Adrian Hayday, Bruno Silva-Santos and Larry Lamb, collaborating and brainstorming approaches to tackle the most pressing hurdles in this burgeoning field.

Don't miss your chance to to enhance process development, overcome with expert learnings from the 4th Gamma Delta T Therapies Summit.

URLs:
Brochure: https://go.evvnt.com/1611492-0?pid=10018
Website: https://go.evvnt.com/1611492-1?pid=10018
Tickets: https://go.evvnt.com/1611492-3?pid=10018


Prices:
Drug Developer Pricing - Conference + Workshop Day: USD 4946.00,
Drug Developer Pricing - Conference Only: USD 2999.00,
Academic Pricing - Conference + Workshop Day: USD 4246.00,
Academic Pricing - Conference Only: USD 2599.00,
Service Provider Pricing - Conference + Workshop Day: USD 6046.00,
Service Provider Pricing - Conference Only: USD 3799.00,
Drug Developer Pricing - Conference + Deep-Dive Day: USD 4946.00,
Academic Pricing - Conference + Deep-Dive Day: USD 4246.00,
Service Provider Pricing - Conference + Deep-Dive Day: USD 6046.00

Speakers: Rajkumar Ganesan, Executive Director of Immunotherapeutics, Amgen, Michael Traxlmayr, Senior Scientist, BOKU, Daniel Olive, Team Leader, CCRM, Daria Paruzina, Senior Product Development Manager, Century Therapeutics, Jay Mills, Director of Process Development, Century Therapeutics, Wee Kiat Tian, Chief Operating Officer, CytoMed, Hunter Jonus, Postdoctoral Fellow, Emory University, Kelly Goldsmith, Professor, Emory University, Adrian Hayday, Principal Group Leader, Francis Crick Institute, Marcel Zwaal, Chief Operating Officer, Gadeta, Sophie Agaugue, Vice President, Preclinical Research, Imcheck Therapeutics, Paul Frohna, Chief Medical Officer, Imcheck Therapeutics, Inbar Alfaguter, Senior Scientist, Immatics, Chris Holland, Manager, Experimental Immunology, Immunocore, Larry Lamb, Chief Scientific Officer, In8Bio, Kate Rochlin, Chief Operating Officer, IN8bio, Bruno Silva-Santos, Group Leader, Instituto do Medicina Molecular, Michael Uhlin, Head of the Division of Clinical Immunology, Karolinska University Hospital, Joshua Kellner, Senior Director Manufacturing, Science and Technology, Kiromic Biopharma, Hans Van Der Vliet, Chief Scientific Officer, Lava Therapeutics, Caroline Hull, Associate Director, Leucid Bio, Daniel Abate-Daga, Associate Member, Moffitt Cancer Center, Jeff Liter, President and Chief Operating Officer, Luminary Therapeutics, Huan Yang, Associate Principal Scientist, Merck, Megan Van Overbeek, Senior Director, Cell Therapy Discovery, Metagenomi, Leticia Tordesillas, Research Scientist, Moffitt Cancer Center, Kok Fei Chan, Research Fellow, Olivia Newton-John Cancer Research Institute, Dorothee Bourges, Lab Head, Pharmacology Immuno-Oncology, Sanofi, Anne Lai, Principal Scientist, Research and Development, Shattuck Labs, Yu Qian, Associate Director, CMC, Cell Therapies, Takeda, Emilio Cosimo, Director of Product Development, TCBiopharm, Andy Bader, Chief Scientific Officer, Triumvira, Chris Ayers, Associate Director of Immunology and Process Develoment, Triumvira, Michael Lotze, Professor of Surgery, Immunology and Bioengineering, University of Pittsburgh, Angela Justice, Chief People Officer, TCR2, Aleks Filipovic,Head of Oncology, PureTech